School of Medicine


Showing 891-900 of 1,146 Results

  • Vidushi Savant

    Vidushi Savant

    Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry

    BioDr. Savant specializes in the treatment of comorbid psychiatric disorders in medically ill patients.

    She is a double board certified in Psychosomatic Medicine and General Psychiatry.

  • Parnika Prashasti Saxena

    Parnika Prashasti Saxena

    Clinical Associate Professor, Psychiatry and Behavioral Sciences

    BioParnika Saxena is board certified in general and geriatric psychiatry. She completed her residency at St Elizabeth's Medical Center (affiliated with Tufts University School of Medicine) in Massachusetts and a clinical geriatric fellowship at the University of California, Los Angeles. She also worked as a research fellow in Clinical Psychopharmacology at Mclean Hospital (affiliated with Harvard Medical School) and also completed a psychoanalytic psychotherapy fellowship from the Boston Psychoanalytic Society and Institute. Her primary research interests lie in pharmacological and interventional treatments for resistant depression. At Stanford, she works on the inpatient service, outpatient geropsychiatry clinic and the electroconvulsive therapy service. She also serves at the program director of the Geriatric Psychiatry Fellowship. In addition to her clinical and research interests, she is passionate about patient advocacy and promoting mental health legislative changes to benefit patient care and has testified in state senate hearings to that end as a physician representative of organizations like the Northern California Psychiatric Association and American Psychiatric Association.

  • Blake K. Scanlon, Ph.D.

    Blake K. Scanlon, Ph.D.

    Adjunct Lecturer, Psych/Public Mental Health & Population Sciences

    BioThe overarching aim of Dr. Scanlon’s research is to develop and evaluate low-cost, pragmatic and clinically translatable methods for improving management of neurodegenerative disease and dementia. To that end, the Caregiver Technology Division of the Scanlon Lab aims to enhance patient- and family-centered care through novel, broadly customizable, and highly scalable caregiver interventions. In parallel, the Neurodegenerative Division of the Scanlon Lab focuses on the development and application of cognitive, neuropsychiatric, and biological markers for the initiation and progression of neurodegeneration.

    Dr. Scanlon received his bachelor’s degree in Neuroscience and doctorate in Clinical Health Psychology from the University of Miami. After concluding his clinical internship in Geropsychology/Neuropsychology at the VA Palo Alto Health Care System (VAPAHCS), he completed fellowships in Aging and Dementia at Stanford University School of Medicine and VAPAHCS. Dr. Scanlon is currently a VA Career Development Awardee in the Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) and Stanford/VA Aging Clinical Research Center where his work focuses on developing and evaluating low-cost, pragmatic and clinically translatable methods for improving management of neurodegenerative disease and dementia. He also serves as Co-Director of the Stanford/VA California Alzheimer's Disease Center, Chair of the VAPAHCS Dementia Committee, and Co-Chair of the Department of Veterans Affairs VISN 21 Dementia Committee.

  • Alan F. Schatzberg

    Alan F. Schatzberg

    Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences

    Current Research and Scholarly InterestsBiological bases of depressive disorders;, glucocorticoid/dopamine interactions in delusional depression;, pharmacologic treatment of depressive disorders.

  • Mariana Schmajuk

    Mariana Schmajuk

    Clinical Assistant Professor, Psychiatry and Behavioral Sciences
    Clinical Assistant Professor, Psychiatry and Behavioral Sciences

    BioMariana Schmajuk received her medical school education at Boston University School of Medicine in 2012. She completed her General Adult Psychiatry Residency program Mount Sinai School of Medicine in New York in 2016, serving as Chief Resident with a focus on the early transition from medical school to residency. She went on to complete her Consult-Liaison fellowship at New York-Presbyterian Hospital Columbia University Medical Center in 2017.

    Dr. Schmajuk joined Stanford University CLP team in 2017. She is a primary member of the emergency medicine consultations, working collaboratively with a nurse practioner, social worker and residents. Clinically, Dr. Schmajuk focuses on treating patients with terminal neurological disorders and oncological processes. Dr. Schmajuk is the director of the Psychosomatic Continuity clinic where residents and fellows are able to assess and longitudinally treat patients with psychiatric sequela in the context of complex medical illness. She has a particular interest in brief psychotherapeutic interventions. She enjoys teaching medical students about CL psychiatry and interviewing skills. At present, Dr. Schmajuk is using techniques of applied improvisation to educate psychiatry residents and others about the building blocks of communication. She also is an active member of the bioethics committee.

  • Logan Schneider

    Logan Schneider

    Adjunct Clinical Associate Professor, Psychiatry and Behavioral Sciences

    Current Research and Scholarly InterestsFrom a research perspective, my long-term career plan is to refine the understanding of normal and dysfunctional sleep, much like the Epilepsy Phenome/Genome Project (EPGP) and Epi4K are doing for the enigmatic epilepsies. Insufficient sleep has been deemed a public health problem with poorly understood behavioral and physiologic sleep disorders lying at the core of the issue. I am currently using well-defined distinct and objective phenotypes (e.g. periodic limb movements, hypocretin-deficient narcolepsy) to acquire the analytic skills necessary to expand my knowledge of both signal processing and genetics, with the former enhancing my ability to identify and/or refine sleep phenotypes, and the latter facilitating the pathophysiological understanding of these phenotypes. As a consequence of a better link between symptoms/phenotypes, physiology, and genetic risks, more personally targeted and effective therapeutics can be developed to address the enriched spectrum of sleep disorders.